{"id":17694,"date":"2025-07-21T09:11:29","date_gmt":"2025-07-21T03:41:29","guid":{"rendered":"https:\/\/dev.sunpharma.com\/?p=17694"},"modified":"2026-01-22T13:52:53","modified_gmt":"2026-01-22T08:22:53","slug":"sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint","status":"publish","type":"post","link":"https:\/\/dev.sunpharma.com\/he\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/","title":{"rendered":"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint"},"content":{"rendered":"<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/07\/Press-Release-Phase-3-Clinical-Studies-PsA-ILUMYA-Topline.pdf\" class=\"read-more-btn\" target=\"_blank\">Read More<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Read More<\/p>","protected":false},"author":4,"featured_media":28,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-17694","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressreleases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint - Sun Pharmaceutical Industries Ltd.<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint - Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"og:description\" content=\"Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-21T03:41:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T08:22:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"626\" \/>\n\t<meta property=\"og:image:height\" content=\"417\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ananthi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ananthi\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/\"},\"author\":{\"name\":\"ananthi\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#\\\/schema\\\/person\\\/c7269b4a3d6a22d46bfb1554af8093fa\"},\"headline\":\"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint\",\"datePublished\":\"2025-07-21T03:41:29+00:00\",\"dateModified\":\"2026-01-22T08:22:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/\"},\"wordCount\":20,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/press_release_caritec.jpg\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/\",\"name\":\"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint - Sun Pharmaceutical Industries Ltd.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/press_release_caritec.jpg\",\"datePublished\":\"2025-07-21T03:41:29+00:00\",\"dateModified\":\"2026-01-22T08:22:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#\\\/schema\\\/person\\\/c7269b4a3d6a22d46bfb1554af8093fa\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/press_release_caritec.jpg\",\"contentUrl\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/press_release_caritec.jpg\",\"width\":626,\"height\":417,\"caption\":\"Sun Pharma introduces a novel class of drug\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#\\\/schema\\\/person\\\/c7269b4a3d6a22d46bfb1554af8093fa\",\"name\":\"ananthi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g\",\"caption\":\"ananthi\"},\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/he\\\/blog\\\/author\\\/ananthi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint - Sun Pharmaceutical Industries Ltd.","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"he_IL","og_type":"article","og_title":"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint - Sun Pharmaceutical Industries Ltd.","og_description":"Read More","og_url":"https:\/\/dev.sunpharma.com\/he\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_published_time":"2025-07-21T03:41:29+00:00","article_modified_time":"2026-01-22T08:22:53+00:00","og_image":[{"width":626,"height":417,"url":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","type":"image\/jpeg"}],"author":"ananthi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ananthi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#article","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/"},"author":{"name":"ananthi","@id":"https:\/\/dev.sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"headline":"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint","datePublished":"2025-07-21T03:41:29+00:00","dateModified":"2026-01-22T08:22:53+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/"},"wordCount":20,"commentCount":0,"image":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","articleSection":["Press Releases"],"inLanguage":"he-IL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/","url":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/","name":"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint - Sun Pharmaceutical Industries Ltd.","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#primaryimage"},"image":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","datePublished":"2025-07-21T03:41:29+00:00","dateModified":"2026-01-22T08:22:53+00:00","author":{"@id":"https:\/\/dev.sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/"]}]},{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#primaryimage","url":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","contentUrl":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","width":626,"height":417,"caption":"Sun Pharma introduces a novel class of drug"},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharmas-phase-3-clinical-studies-evaluating-tildrakizumab-100-mg-ilumya-in-active-psoriatic-arthritis-meet-their-primary-endpoint\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"},{"@type":"Person","@id":"https:\/\/dev.sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa","name":"ananthi","image":{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"ananthi"},"url":"https:\/\/dev.sunpharma.com\/he\/blog\/author\/ananthi\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/17694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=17694"}],"version-history":[{"count":1,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/17694\/revisions"}],"predecessor-version":[{"id":17695,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/17694\/revisions\/17695"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media\/28"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=17694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/categories?post=17694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/tags?post=17694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}